They state in their quarterly update that COVID-19 has had limited impact on their business and they are right. Prior to COVID-19 they were telling us sweet FA and now during COVID they still telling us sweet FA, so no material impact whatsoever.
So little information. Phase 2 was meant to commence prior to end of Q2. We have no idea if they are on track and how patient recruitment is going. I understand they will be having a meeting with the FDA to outline requirements needed to commence phase 2. Also interesting to note that they have changed the name of PBT434 to ATH434.
Also no mention that they are looking at PBT2 effect on Covid-19, only its antibacterial properties.
ATH Price at posting:
2.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)